Biofortuna’s HLA molecular diagnostic kit products are based on a freeze-dried technology that stabilizes the PCR reaction mix, including polymerase. The kits are stable at ambient temperature, and require only the addition of DNA to the predispensed PCR reaction mix. The freeze-dried manufacturing technology is separately being offered as a contract service for diagnostic companies.

Last month Biofortuna raised £2.1 million in an investment round with new and existing investors to support expansion of its manufacturing operations and fund the development of new products in areas including companion diagnostics, antibody screening, and disease identification.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.